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Abstract
Objectives: To analyze selective COX 2 inhibitor nonsteroidal anti-inflammatory drugs (NSAID)  in terms of their
mechanism of action, principal indications, posology and most common adverse effects.
Sources: MEDLINE and LILACS databases and Food and Drug Administration (FDA) and National Agency for Sanitary
Vigilance (ANVISA - AgŒncia Nacional de Vigilância SanitÆria) websites. The most important articles were selected and
preference was given to articles published within the last 5 years.
Summary of the findings: The principal indications for NSAID are for control of pain and acute and chronic
inflammation. There is no overwhelming evidence that demonstrates the superiority of one NSAID over another in terms
of effectiveness. To date none of the COX 2 inhibitors has been liberated for use in the pediatric age group. Only
meloxicam and etoricoxib can be prescribed for adolescents (13 and 16 years, respectively). Selective COX 2 inhibitors
are indicated for patients with adverse effects that have proven to be associated with nonselective NSAID use. Selective
COX 2 inhibitors can be prescribed in  some cases of allergy to aspirin, but they must be used with care. Principal adverse
effects include cardiovascular events and thrombotic phenomena.
Conclusions: Selective COX 2 inhibitors are medicines that have been used in certain well-defined clinical situations
and which may offer certain advantages over nonselective NSAID. Nevertheless, taking into consideration the higher cost
involved and the potential for adverse cardiovascular effects, they should be employed only in accordance with strict
criteria.
J Pediatr (Rio J). 2006;82(5 Suppl):S206-12: Nonsteroidal anti-inflammatories, COX 2 inhibitors, indications,
adverse effects.
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Introduction
Nonsteroidal anti-inflammatory drugs (NSAID)
comprise a heterogeneous group of medications, the
majority of which are organic acids with analgesic,
antipyretic and anti-inflammatory actions. These drugs
are widely used to control fever and acute or chronic pain.1
They are the most sold medications worldwide and,
together with analgesics and antipyretics, account for
approximately 30% of all medicines used (prescribed by
physicians or otherwise).1
Synthesis of prostaglandins and leukotrienes
When there is damage to the cell membrane, which is
basically made up of phospholipids, the enzyme
phospholipase A2, which is present in leukocytes and
platelets, is activated by proinflammatory cytokines, such
as interleukin (IL)-1. This enzyme leads to the degradation
of phospholipids, resulting in production of arachidonic
acid . This, when metabolized, forms leukotrienes through
the action of the enzyme lipoxygenase, and prostaglandins,
prostacyclins and thromboxanes, through the action of the
cyclooxygenase enzyme (COX).
COX is the first enzyme involved in producing
prostaglandins from arachidonic acid.2-4 It converts, by
oxygenation, the arachidonic acid into two unstable
components: prostaglandin G2 and prostaglandin H2.
These prostaglandins are later transformed by isomerases
into prostacyclin, thromboxane A2, and prostaglandins
D2, E2 and F2α. Prostaglandin E2 is important because of
its pyrogenic action and in increasing sensitivity to pain.
Arachidonic acid also leads to production of leukotrienes,
via lipoxygenase enzyme (Figure 1).
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Figure 1 - Mechanism of action of nonsteroidal
anti-inflammatories
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An important advance in anti-inflammatory therapy
was the discovery of two isoforms of COX (also known as
synthetase prostaglandins): COX 1 and COX 2. Whereas
COX 1 has 17 amino acids at the terminal amino section,
COX 2 has 18 amino acids at the terminal carboxyl section.
Although they are very similar in terms of their protein
structure, these enzymes are coded by different genes.
Genetically, COX 1 and COX 2 are approximately 60%
homologous and their genes are located at chromosomes
9 and 1, respectively.2
COX 1 and COX 2 exhibit minor differences, which
confer distinct functions on them. COX 1 is present in
almost all tissues (blood vessels, platelets, stomach,
intestine, kidneys) and, for this reason, is defined as a
constitutive enzyme. Cyclooxygenase 1 is associated with
prostaglandin production and results in a variety of
physiological effects, such as gastric protection, platelet
aggregation, vascular homeostasis and maintenance of
renal blood flow.
In contrast, COX 2 is present at the site of inflammation,
and because of this is defined as an inducible enzyme. It
is primarily expressed by cells that are involved in the
inflammatory process, such as macrophages, monocytes
and synoviocytes. Nevertheless, it is known that COX 2
can also be found in other tissues and organs, such as
kidneys, brain, ovaries, uterus, cartilage, bones and
vascular endothelium. COX 2 is induced by cytokines
(IL-1, IL-2 and tumor necrosis factor [TNF]) and other
mediators (such as  growth factor and endotoxins) at
the site of inflammation. It is probably also expressed in
the central nervous system and plays a role in central
mediation of pain and fever. Expression of COX 2 can,
however, be suppressed by glucocorticoids, IL-4, IL-10
and IL-14. More recently a third COX type has been
described, called COX 3.5
Prostaglandin functions
Prostaglandins are involved in several physiological
and pathological processes, including vasodilation or
vasoconstriction, contraction and relaxation of bronchial
or uterine musculature, hypotension, ovulation, bone
metabolism, increase in renal blood flow (resulting in
diuresis, natriuresis, caliuresis and stimulation of renin
secretion), suppression of gastric acid secretion,
immunoresponse, hyperalgesia, regulation of chemotactile
cellular activity, endocrine response and angiogenesis,
among others.
In the gastrointestinal tract, prostaglandins I2 and E2
are cytoprotective of the gastric mucosa   because they
suppress acid secretion, increase local blood flow, provoke
mucus production and increase synthesis of glutathione
(and consequently the capacity to eliminate free radicals)
and because they increase bicarbonate synthesis and
blood flow to the surface layers of the gastric mucosa. In
the kidneys they increase glomerular filtration because of
their vasodilator effect. Finally, within the cardiovascular
system, they can cause several hemodynamic effects,
such as vasodilation. They also provoke smooth muscle
relaxation. Thromboxane A2 (a substance that promotes
coagulation) is produced from platelet COX, and acts as a
potent aggregant agent.
Prostaglandins also have pathophysiologic effects such
as erythema and increased local blood flow, hyperalgesia,
probably due to sensitization of pain receptors, and
increased body temperature at the hypothalamus through
cytokine stimulation. When prostaglandin production is
increased, there is increased sensitivity to pain and fever
and increased inflammatory response. Nevertheless,
prostaglandins are also capable of anti-inflammatory action
due to suppression of IL-1 and TNF synthesis.
Mechanism of action
The mechanism of action of NSAIDs consists in
suppression of COX enzymes, resulting in reduction of the
production of prostaglandins, thus controlling inflammation,
pain and fever.
There are some anti-inflammatories that selectively
or specifically inhibit wither COX 1 or  COX 2.6 Only COX
1 inhibits thromboxane formation. COX 1 inhibition is
associated with increased risk of gastrointestinal bleeding
and damage. Selective and specific COX 2 inhibitors
were developed in an attempt to reduce the incidence of
adverse effects of COX 1 inhibition.2 These inhibitors
include piroxicam, meloxicam, diclofenac, naproxen
and nimesulide (first-generation selective COX 2
inhibitors), and  celecoxib, etoricoxib, valdecoxib,
parecoxib and lumiracoxib7 (second-generation, more
specific, selective COX 2 inhibitors).
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Table 1 - Dose and posology of  nonsteroidal anti-inflammatories (information obtained from labels)
Medication* Daily dosage Number of Minimum recommended
doses per day age (years)
†
Acetylsalicylic acid
‡
80-100 mg/kg 3 to 4 12
Naproxen 10-20 mg/kg 2 2
Ibuprofen 20-40 mg/kg 3 to 4 6 months
Indomethacin
§
1.5-3 mg/kg 3 14
Meloxicam 7.5-15 mg 1 13
Celecoxib 200-400 mg 2 18
Valdecoxib 40 mg 1 18
Parecoxib
||
40 mg (IM or IV) 1 18
Etoricoxib 60-120 mg 1 16
Lumiracoxib 100-400 mg 1 18
* The selective COX 2 inhibitor rofecoxib (12.5 – 50 mg/day in a single dose) was withdrawn from the market in 2004 by the manufacturer.
† Ages recommended by the Food and Drug Administration (FDA) in the United States of America and by the National Agency for Sanitary
Vigilance (ANVISA - Agência Nacional de Vigilância Sanitária) in Brazil.
‡ In clinical practice acetylsalicylic acid is used in children with inflammatory diseases of all ages, but it is not recommended in cases with
suspected viral etiology because of the increased risk of Reye syndrome.
§ Indomethacin is used to treat persistent ductus arteriosus in newborns and to control of fever and pain in children and adolescents with juvenile
idiopathic arthritis (systemic type) and arthritis related to enthesitis.
|| Parecoxib is metabolized into valdecoxib in less than 1 hour and is contraindicated in cases of sulfonamide allergy.
The NSAID dose necessary to reduce inflammation is
larger than that needed to inhibit prostaglandin formation,
suggesting that other mechanisms  mediate the anti-
inflammatory effects. In addition to suppressing
prostaglandin production, current anti-inflammatories
inhibit specific proteases involved in breaking down
proteoglycans  and collagens in cartilage, and inhibit the
generation of oxygen free radicals, particularly superoxide.8
These medications also interfere with the liberation of
bradykinin, with the lymphocyte response to antigen
stimulus, with phagocytosis and with chemotaxis of
granulocytes and monocytes.8
Pharmacokinetic
The following are characteristics of NSAIDs:
 rapid absorption;
 the majority of absorption takes place in the stomach
and the upper portion of the small intestine;
 absorption is reduced when taken at night;
 the majority binds with plasma proteins;
 the pharmacological effect comes from the drug in its
free state (unbound);
 metabolism is predominantly hepatic and is faster in
children;
 excretion is renal;
 elimination is faster in children than in adults, requiring
more frequent doses.
A study of 11 children with neoplasias assessed the
pharmacokinetics of celecoxib.9 The authors observed
significant differences in terms of the availability of
celecoxib in children compared with in adults, such as
elimination that is twice as fast and a half-life that is half
as long. They also observed that absorption of the
medication is optimized when taken with a fat-rich meal.
In a study undertaken with 18 patients with juvenile
rheumatoid arthritis, the pharmacokinetics of meloxicam
suspension was evaluated, with greater elimination of the
medication being observed in the younger children,
although with a similar half-life to other age groups.10
Indications
The most common indications for NSAIDs in childhood
and adolescence are control of fever, acute and chronic
pains and inflammation. Acetylsalicylic acid, naproxen,
ibuprofen and tolmetin are the only ones approved for
pediatric use by the Food and Drug Administration (FDA).
Despite not being licensed for the pediatric age group,
indomethacin is used to control fever and pain in children
and adolescents with juvenile idiopathic arthritis (JIA).
Selective COX 2 inhibitors are indicated for patients
who exhibit adverse effects that are confirmed to be
related to nonselective NSAID use, such as gastric
intolerance that cannot be controlled by combination with
gastroprotective  medication. In the pediatric age group,
the use of COX 2 is limited since a majority of these
medicines are contraindicated before 18 years of age.
Table 1 lists dosage, posology and minimum age
recommended for NSAIDs by the FDA and the Brazilian
National Agency for Sanitary Vigilance (AgŒncia Nacional
de Vigilância SanitÆria  ANVISA).
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Indication NSAIDs Characteristic features References
Fever Ibuprofen,  The effectiveness of ibuprofen Perrott et al.11
indomethacin is similar to paracetamol.
 Indomethacin is the drug of choice
for the control of fever in children
with systemic JIA and of pain
in adolescents with ERA.
Acute and Naproxen, ibuprofen,  Medicines used for the control Perrott et al.11,
chronic pain indomethacin, weak to moderate pain. Bricks & Silva12
selective COX 2  Most common indications: migraine,
inhibitors dysmenorrhea and postoperative pain.
 The effectiveness of NSAIDs is comparable
with paracetamol. They can be used
in combination with paracetamol.
Pediatric Acetylsalicylic acid  Acetylsalicylic acid is the NSAID of choice for Anthony &
rheumatology (ASA), naproxen, the treatment of arthritis from rheumatic fever. Schanberg13,
ibuprofen, indomethacin,  Used to treat patients with Ruperto et al.14,
selective COX 2 Henoch-Schönlein purpura, Reiff et al.15,
inhibitors juvenile systemic lupus erythematosus. Hochberg16
 Naproxen is the first-line drug for patients
with oligoarticular and polyarticular JIA.
 Meloxican has proven safe and effective in
patients with oligoarticular and polyarticular JIA
at doses of 0.125 and 0.25 mg/kg/day.
 Chronic use demands serial urinary
sediment testing (because of a risk of
interstitial nephritis with hematuria).
Infections of Ibuprofen,  Safety and efficacy Weckx et al.17
the upper selective COX 2 similar to paracetamol
respiratory tract inhibitors for relief from symptoms.
Table 2 - Habitual indications for nonsteroidal anti-inflammatories
NSAIDs = nonsteroidal anti-inflammatories; JIA = juvenile idiopathic arthritis; ERA = enthesitis-related arthritis.
Nonsteroidal anti-inflammatories are routinely
employed by many specialties. Pediatricians,
otorhinolaryngologists, rheumatologists, gynecologists and
orthopedists prescribe these medicines the most often.
Habitual indications for NSAIDs are shown in Table 2.11-17
Specific COX 2 inhibitors and atopic disease
We should be cautious when prescribing NSAIDs for
atopic patients with sensitivity to acetylsalicylic acid (ASA),
since there is a possibility of exacerbating the allergic
condition. In these cases, selective COX 2 inhibitor NSAID
could be a treatment option since the response mechanism
of sensitivity to ASA particularly involves the COX 1
enzyme. It is important to point out that this
recommendation is based on the results of few studies
involving small numbers of patients, and there are reports
of sporadic cases with significant worsening of asthma
with the use of selective COX 2 inhibitors.
Martin-Garcia et al. did not observe asthma exacerbation
after use of celecoxib (200 mg/day for 7 days), a highly
selective COX 2 inhibitor, in 33 patients with asthma
induced by NSAIDs.18 In a placebo-controlled study,
Bavbek et al. assessed the safety of three NSAIDs
(nimesulide, meloxicam and rofecoxib) with a group of
137 patients with history of allergy to this class of
medication.19 Cutaneous and respiratory reactions were
observed in 24 patients: nimesulide 14.3%, meloxicam
8.1% and rofecoxib 2%. Only the subset given rofecoxib
did not exhibit any exacerbation of preexisting asthma.
Etoricoxib, another selective COX 2 inhibitor, was also
shown to be safe when used on patients with urticaria and
angioedema.20
Urticaria exacerbation related to nonselective COX
inhibitors has been known for a long time. Nonselective
anti-inflammatories are COX inhibitors and the theoretical
explanation for this mechanism may be based on the fact
that these enzymes are responsible for synthesis of
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proinflammatory (PGD2) and anti-inflammatory
prostaglandins (PGE2). PGE2 inhibits synthesis of
leukotrienes (LTB4); therefore blocking production of
PGE2 could increase production of leukotrienes, with
deterioration of clinical symptoms. Selective COX 2
inhibitors preferentially block synthesis of PGD2 and, to a
lesser extent, PGE2. This mechanism could explain
improvements in the urticaria of some patients treated
with a combination of antileukotrienes and COX 2 specific
NSAIDs.21
Adverse effects
There is no overwhelming evidence that demonstrates
the superiority of one NSAID over another in terms of
effectiveness and, very often, the choice is based on lower
frequency and intensity of side effects and on the cost of
the medication.
Although age over 60 years, previous history of
gastrointestinal complications and concurrent corticosteroid
use are the principal risk factors for severe gastrointestinal
complications from NSAID use, we must not forget that
chronic use of these medicines can result in esophagitis,
gastritis or duodenitis, gastric or duodenal ulcers, even if
subclinical, in children and adolescents. A study carried
out at our service with 14 children with juvenile rheumatoid
arthritis on chronic NSAID use found that while just 27%
presented gastrointestinal complaints, on endoscopy
macroscopic lesions were observed in 43% and microscopic
injuries in 57% of the patients. Although in general
children complain less than adults, especially about
gastropathy secondary to NSAID use, this does not mean
that they are free from endoscopic lesions, as has been
demonstrated.22
The major debate and the greatest uncertainties
perhaps reside in sporadic or short-term (a few days)
use of NSAIDs. What are the true risks? There are no
studies in the literature that prove the safety of these
medications under these treatment regimes. This does
not rule out the possibility of erosive damage and even
bleeding from gastro-duodenal mucosa after three or
four doses.
Gastrointestinal events
Advanced age, previous peptic ulcer, previous bleeding
and concurrent use of another NSAID or corticosteroids
are risk factors for gastric complications such as mucosal
ulceration, reflux esophagitis, esophageal thinning and
peptic ulcers.23 Since these effects are primarily mediated
by COX 1 inhibition, it is believed that selective COX 2
inhibitors are a safer alternative. Nevertheless, although
some studies have reported lower frequencies of
gastrointestinal complications with COX 2 inhibitors than
with traditional NSAIDs, recent concerns regarding
cardiovascular safety have limited the use of these
medications.
Renal events
Conditions such as congestive heart failure, cirrhosis,
diabetes, hypertensive nephropathy, advanced age and
volume depletion constitute risk factors that can
predispose patients to renal complications. Salt retention,
acute reversible renal insufficiency and tubulointerstitial
nephritis are some of the undesirable effects. While
selective specific COX 2 inhibitors may cause less renal
alterations, they are not free from inducing some of
these alterations.24
Cutaneous events
Photosensitivity, erythema multiforme, urticaria and
Steven-Johnson syndrome have all been observed with
NSAIDs in general. One study with 381 adults who
exhibited pseudoallergic reactions to NSAIDs showed
that nimesulide and meloxicam were well-tolerated.23
Hepatic events: l iver toxicity with elevated
transaminases, cholestasis and necrosis may occur,
especially with COX 1 inhibitors.
Hematological events
Hemolytic anemia, neutropenia, thrombocytopenia and
medulla aplasia are observed rarely with NSAIDs nowadays,
especially with COX 2 inhibitors.
Central nervous system events: headaches, tingling
sensations and dizziness, although possible, are rarely
reported by children and adolescents.
Cardiovascular events
Countless studies have been published recently on
the cardiovascular toxicity of several NSAIDs, especially
the selective COX 2 inhibitors.25 It has not yet been
established whether the risk is specific to one COX 2
inhibitor in particular, applicable to all COX 2 inhibitors,
or characteristic of all NSAIDs.26 Acute myocardial
infarction, cerebrovascular ischemia, hypertension and
exacerbation of congestive heart failure appear to be
associated with the use of at least some NSAIDs.27 The
mechanism responsible for the cardiovascular toxicity
of COX 2 inhibitors has not yet been fully explained. The
most probable hypothesis involves an imbalance between
prostacyclin and thromboxane A2. Prostacyclin is a
vasodilator and inhibits platelet aggregation and vascular
proliferation, while thromboxane A2 causes platelet
aggregation, vasoconstriction and proliferation of smooth
muscle. Platelets, which only express COX 1, are the
primary products of thromboxane A2, and endothelial
Nonsteroidal anti-inflammatories  HilÆrio MOE et al.
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Adverse event Meloxicam Meloxicam Naproxen p
0.125 mg/kg 0.25 mg/kg 10 mg/kg
(n = 73) (n = 74) (n = 78)
Gastrointestinal 28 (38) 27 (37) 25 (32) 0.7
Infection/infestation 30 (41) 38 (51) 39 (50) 0.4
Respiratory alterations 22 (30) 19 (26) 26 (33) 0.6
Headaches 9 (12) 10 (14) 5 (6) 0.3
Cutaneous alterations 4 (6) 5 (7) 13 (17) 0.049*
Bleeding 3 (4) 2 (3) 9 (12) 0.07
Table 3 - Principal adverse effects observed in children given meloxicam or naproxen
* p < 0.05 = significant.
Ruperto et al.14
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